CA2152373C - Traitement de l'infection provoquee par le cytomegalovirus - Google Patents

Traitement de l'infection provoquee par le cytomegalovirus

Info

Publication number
CA2152373C
CA2152373C CA002152373A CA2152373A CA2152373C CA 2152373 C CA2152373 C CA 2152373C CA 002152373 A CA002152373 A CA 002152373A CA 2152373 A CA2152373 A CA 2152373A CA 2152373 C CA2152373 C CA 2152373C
Authority
CA
Canada
Prior art keywords
arg
peptide
cmv
oligopeptide
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002152373A
Other languages
English (en)
Other versions
CA2152373A1 (fr
Inventor
Michael Twist (Deceased)
Martin Sumner-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allelix Biopharmaceuticals Inc
Original Assignee
Allelix Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharmaceuticals Inc filed Critical Allelix Biopharmaceuticals Inc
Publication of CA2152373A1 publication Critical patent/CA2152373A1/fr
Application granted granted Critical
Publication of CA2152373C publication Critical patent/CA2152373C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des peptides anti-cytomégalovirus (CMV). Dans un mode de réalisation préféré, le peptide est l'acétyle-[D-Arg]¿9?-NH¿2?. L'invention concerne également l'utilisation desdits peptides, soit individuellement, soit combinés à d'autres composés anti-CMV, en tant que procédé efficace de lutte contre l'infection provoquée par le CMV.
CA002152373A 1993-10-22 1994-10-21 Traitement de l'infection provoquee par le cytomegalovirus Expired - Fee Related CA2152373C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13975793A 1993-10-22 1993-10-22
US08/139,757 1993-10-22

Publications (2)

Publication Number Publication Date
CA2152373A1 CA2152373A1 (fr) 1995-04-27
CA2152373C true CA2152373C (fr) 1998-12-15

Family

ID=22488150

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002152373A Expired - Fee Related CA2152373C (fr) 1993-10-22 1994-10-21 Traitement de l'infection provoquee par le cytomegalovirus

Country Status (4)

Country Link
EP (1) EP0675731A1 (fr)
AU (1) AU685862B2 (fr)
CA (1) CA2152373C (fr)
WO (1) WO1995011038A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
EP1210121A2 (fr) 1999-08-24 2002-06-05 Cellgate Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
JP5401457B2 (ja) * 2007-07-26 2014-01-29 ルバンス セラピュティックス インク． 抗菌ペプチド、組成物及びその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501938A (ja) * 1990-10-24 1994-03-03 アレリックス　バイオファーマシューティカルズ　アイエヌシー． ペプチドよりなるｈｉｖ複製阻害剤
WO1993021941A1 (fr) * 1992-04-23 1993-11-11 Allelix Biopharmaceuticals Inc. Traitement de l'infection due au virus herpes
AU5829994A (en) * 1992-12-22 1994-07-19 Allelix Biopharmaceuticals Inc. Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide

Also Published As

Publication number Publication date
AU685862B2 (en) 1998-01-29
AU7987694A (en) 1995-05-08
WO1995011038A1 (fr) 1995-04-27
EP0675731A1 (fr) 1995-10-11
CA2152373A1 (fr) 1995-04-27

Similar Documents

Publication Publication Date Title
US5633230A (en) Treatment of cytomegalovirus infection
US4795740A (en) Antiviral peptides and means for treating herpes infections
EP0554284B1 (fr) Inhibiteurs de la replication du vih a base de peptides
US8299214B2 (en) Influenza infection-inhibiting peptide, influenza virus infection inhibitor, liposome, and influenza preventive/therapeutic agent
US8748565B2 (en) Pharmacologically active antiviral peptides and methods of their use
US5646120A (en) Peptide-based inhibitors of HIV replication
EP0637247B1 (fr) Traitement de l'infection due au virus herpes
CA2152373C (fr) Traitement de l'infection provoquee par le cytomegalovirus
US5831001A (en) Treatment of herpesvirus infection
WO1992014751A1 (fr) Peptides a usage therapeutique
US9221874B2 (en) Antiviral peptides against influenza virus
Hayashi et al. Yucca leaf protein (YLP) stops the protein synthesis in HSV-infected cells and inhibits virus replication
US5066783A (en) Antiviral peptides and means for treating herpes infections
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
US11331371B2 (en) Labyrinthopeptins as anti-viral agents
WO2005060541A2 (fr) Peptides et procedes pour induire une resistance cellulaire a l'infection
CA2047203A1 (fr) Facteur de croissance fibroblastique utilise dans la prevention et le traitement d'infections virales
CN116023439A (zh) 一种抑制新型冠状病毒SARS-CoV-2感染的多肽及其应用
EP1862471A2 (fr) Peptides antiviraux pharmacologiquement actifs et leurs procédés d'utilisation
JPS62289597A (ja) 抗ウイルス性ペプチド及びヘルペス感染治療法
AU2006202024A1 (en) Pharmacologically active antiviral peptides and methods of their use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed